CN Patent

CN106232125B — 用于调节pkk表达的组合物和方法

Assigned to Ionis Pharmaceuticals Inc · Expires 2020-10-16 · 6y expired

What this patent protects

本文公开用于减少PKK mRNA和蛋白质表达的反义化合物和方法。此类方法、化合物以及组合物适用于治疗、预防或减轻PKK相关疾病、病症以及病状。

USPTO Abstract

本文公开用于减少PKK mRNA和蛋白质表达的反义化合物和方法。此类方法、化合物以及组合物适用于治疗、预防或减轻PKK相关疾病、病症以及病状。

Drugs covered by this patent

Patent Metadata

Patent number
CN106232125B
Jurisdiction
CN
Classification
—
Expires
2020-10-16
Drug substance claim
No
Drug product claim
No
Assignee
Ionis Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.